关于公司高级管理人员辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳翰宇药业股份有限公司（以下简称"公司"或"翰宇药业"）于近日收 到副总裁张宝乐先生提交的书面辞职报告。张宝乐先生因个人原因，申请辞去公 司副总裁一职，其辞职报告自送达公司董事会之日起生效。 张宝乐先生原定任期至第六届董事会届满之日止，截止本公告披露日，张宝 乐先生未持有公司股份，其配偶或其他关联人未持有本公司股份，不存在应履行 而未履行的承诺事项。辞职后张宝乐先生将不再担任公司及子公司任何职务，其 所负责的相关工作已进行良好的工作交接，其辞职不会影响公司相关工作的正常 运行。 证券代码：300199 证券简称：翰宇药业 公告编号：2025-035 深圳翰宇药业股份有限公司 特此公告。 深圳翰宇药业股份有限公司董事会 2025年8月16日 公司及董事会对张宝乐先生在任职期间为公司发展所做的贡献表示衷心感 谢！ ...

Market Performance - The ChiNext Index rose by 2.61%, closing at 2534.22 points, with a total trading volume of 660.17 billion yuan, an increase of 8.84 billion yuan compared to the previous trading day [1] - Among the tradable ChiNext stocks, 1247 stocks closed higher, with 35 stocks rising over 10%, including Henghe Precision, Yidong Electronics, and Zhongfu Circuit, which hit the daily limit [1] Trading Activity - The average turnover rate for the ChiNext today was 5.45%, with 60 stocks having a turnover rate exceeding 20% [1] - C Guangjian Technology, a new stock listed for 5 days, had the highest turnover rate at 55.24%, closing down by 1.41% [1][2] Institutional Participation - Nine high turnover rate stocks appeared on the Dragon and Tiger List, indicating institutional involvement, with significant net purchases in stocks like Shuangyi Technology and Yihua New Materials [3] - The top net purchases were led by Chuanhuan Technology, with a net inflow of 136 million yuan from the Shenzhen Stock Connect [3] Financial Performance - Among high turnover stocks, Shuangyi Technology, Yangfan New Materials, and Taicheng Technology reported significant net profit growth of 324.50%, 208.94%, and 118.02% respectively [4] - The highest projected net profit growth was for Hanyu Pharmaceutical, with an expected increase of 1567.36% [4] Stock Highlights - Key stocks with notable performance included: - C Guangjian Technology: closed at 37.00 yuan, down 1.41%, turnover rate 55.24%, net outflow of 28.78 million yuan [4] - Zhejiang Huaye: closed at 64.83 yuan, up 13.92%, turnover rate 54.35%, net inflow of 51.36 million yuan [4] - Shuangyi Technology: closed at 38.68 yuan, up 15.39%, turnover rate 40.64%, net inflow of 21.80 million yuan [4]

（文章来源：每日经济新闻） 每经AI快讯，8月15日，创新药概念股震荡拉升，阳光诺和、广生堂涨超10%，神州细胞、众生药业、 翰宇药业、微芯生物等多股涨逾6%。 ...

Group 1 - Hanyu Pharmaceutical announced a partnership with cryptocurrency exchange KuCoin to tokenize intangible assets related to innovative drugs, which significantly boosted its stock price and market capitalization to approximately 21.5 billion yuan by August 11 [2] - The company reported a net profit of over 140 million yuan for the first half of 2023, driven by a major contract for a weight-loss drug in the U.S. [3] - Hanyu Pharmaceutical is set to become the first company to produce a generic version of liraglutide injection approved by the U.S. FDA by the end of 2024, which will aid in blood sugar management for relevant populations [3] Group 2 - The three controlling brothers of Hanyu Pharmaceutical, from Guangdong, hold a combined 20.76% stake in the company, resulting in an increase of 2 billion yuan in their wealth over the past two months [5]

Core Viewpoint - Hanyu Pharmaceutical is experiencing a significant turnaround, driven by the successful launch of its weight-loss drug, Liraglutide injection, in the U.S. market, which is expected to boost its financial performance and market position [1][3]. Group 1: Company Overview - Hanyu Pharmaceutical, controlled by the Zeng brothers, has recently entered an upward cycle after overcoming previous financial difficulties, including seven consecutive years of losses [3]. - The company reported a net profit of over 140 million yuan for the first half of 2023, attributed to a major contract for a weight-loss drug in the U.S. [3]. - The Zeng brothers collectively hold 20.76% of the company's shares, which has increased their wealth by approximately 2 billion yuan in the past two months [3]. Group 2: Product Development and Market Strategy - Hanyu's Liraglutide injection is set to be the first generic version approved by the FDA by the end of 2024, targeting obesity and diabetes management [5][9]. - The pricing strategy for Liraglutide is significantly lower than the original drug, priced at about 50% to 33% of the original Novo Nordisk product, which is expected to capture a larger market share in North America [7]. - The global market for Liraglutide was valued at approximately $5.991 billion in 2023, with the U.S. accounting for about $3.204 billion [7]. Group 3: Partnerships and Future Prospects - Hanyu has partnered with Hikma Pharmaceuticals, signing contracts worth 338 million yuan to expand its presence in the U.S. market [9]. - The company is adopting a low upfront price with high backend revenue-sharing model, indicating a strategic approach to market penetration [9]. - Hanyu plans to submit applications for additional products, including Semaglutide, in both the U.S. and China, aiming for a dual-market strategy to enhance global reach [18]. Group 4: Historical Context and Financial Recovery - Hanyu Pharmaceutical was founded in 2003 and became the first Chinese synthetic peptide company to go public in 2011 [18]. - The company faced significant challenges after 2018 due to price reductions from national healthcare policies, leading to a loss of 885 million yuan in 2019 [22]. - The market for GLP-1 drugs is projected to reach $90 billion in the U.S. by 2030, indicating a substantial growth opportunity for Hanyu [22].

Group 1 - The article highlights that 37 stocks appeared on the Longhu list this week, with 25 showing net purchases from the Shenzhen Stock Connect [1] - The top three stocks with the highest net purchases were Hanyu Pharmaceutical, Dongxin Peace, and Dongfang Precision, with net purchases of 233.36 million, 187.60 million, and 160.29 million respectively [1] - The average increase for stocks with net purchases from the Shenzhen Stock Connect was 15.47%, outperforming the Shanghai Composite Index, which rose by 2.11% [1] Group 2 - The stock with the largest increase was Guojijinggong, which saw a price increase of 61.05% over the week [1] - A total of 12 stocks experienced net sales, with the largest net sales recorded for Shanhe Intelligent and Giant Network, amounting to 191.86 million and 176.14 million respectively [2] - The article provides a detailed table of stocks with their respective net purchases, weekly price changes, and turnover rates, indicating significant trading activity [1][2]

Market Overview - On August 8, the chemical pharmaceutical sector rose by 0.24% compared to the previous trading day, with Lianhuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3635.13, down 0.12%, while the Shenzhen Component Index closed at 11128.67, down 0.26% [1] Stock Performance - Notable declines in individual stocks include: - Shanghai Yizhong: closed at 72.23, down 5.42% with a trading volume of 80,000 shares and a turnover of 573 million yuan - Yifang Bio: closed at 39.80, down 5.37% with a trading volume of 203,000 shares and a turnover of 818 million yuan - Qianhong Pharmaceutical: closed at 10.19, down 4.77% with a trading volume of 1,197,800 shares and a turnover of 1.23 billion yuan [1] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 230 million yuan from institutional investors and a net outflow of 93.16 million yuan from retail investors, while retail investors saw a net inflow of 323 million yuan [1] - Key stocks with significant capital flow include: - Meinuohua: net inflow of 236 million yuan from institutional investors, with a 18.01% share - Lianhuan Pharmaceutical: net inflow of 197 million yuan from institutional investors, with a 13.40% share [2] - Other notable stocks include Han Yu Pharmaceutical and Bo Rui Pharmaceutical, with net inflows of 171 million yuan and 131 million yuan from institutional investors, respectively [2]

| 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 600276 | 恒瑞医药 | -1.25 | 0.79 | -33641.55 | | 300199 | 翰宇药业 | -0.94 | 19.11 | -20942.91 | | 300255 | 常山药业 | -2.59 | 2.57 | -14442.33 | | 002821 | 凯莱英 | -2.35 | 2.83 | -13268.62 | | 300122 | 智飞生物 | -1.06 | 2.35 | -12153.90 | | 000813 | 德展健康 | -1.65 | 6.52 | -10973.38 | | 688076 | ST诺泰 | -2.70 | 4.12 | -7693.61 | | 688202 | 美迪西 | -4.41 | 5.72 | -7684.27 | | 603538 | 美诺华 | -5.28 | 13.44 | -7141.76 | | 300765 | 新诺威 | -6.81 | 0.92 | ...

截至8月7日收盘，创新药概念下跌1.41%，位居概念板块跌幅榜前列，板块内，千红制药跌停，华海药 业、亚太药业、康弘药业等跌幅居前，股价上涨的有36只，涨幅居前的有润都股份、海辰药业、粤万年 青等，分别上涨9.98%、7.22%、6.19%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 稀土永磁 | 3.24 | 减肥药 | -1.70 | | 脑机接口 | 2.69 | CRO概念 | -1.66 | | 高压氧舱 | 2.56 | 创新药 | -1.41 | | 太赫兹 | 1.65 | 仿制药一致性评价 | -1.34 | | 血氧仪 | 1.62 | 重组蛋白 | -1.29 | | 存储芯片 | 1.40 | 中船系 | -1.28 | | MCU芯片 | 1.18 | 阿尔茨海默概念 | -1.18 | | 无线耳机 | 1.08 | 特钢概念 | -1.02 | | 汽车芯片 | 1.02 | 细胞免疫治疗 | -1.02 | | DRG/DIP | 1.00 | PET铜箔 | -0.99 ...

| 603538 | 美诺华 | -5.28 | 13.44 | -7141.76 | | --- | --- | --- | --- | --- | | 000953 | 河化股份 | 1.00 | 21.58 | -6783.63 | | 688222 | 成都先导 | -3.49 | 6.59 | -6676.58 | | 300363 | 博腾股份 | -1.62 | 4.18 | -6054.08 | | 600196 | 复星医药 | -0.98 | 1.29 | -5749.1 1 | | 688185 | 康希诺 | -2.80 | 5.15 | -5649.33 | | 688131 | 皓元医药 | -2.95 | 3.76 | -5426.18 | | 300683 | 海特生物 | -3.97 | 13.76 | -5362.08 | | 688553 | 汇宇制药 | -1.87 | 2.83 | -5128.77 | | 301096 | 百诚医药 | -2.81 | 6.89 | -4796.39 | | 300149 | 睿智医药 | -1.65 | 8.06 | -3859. ...